|(R)-2-(4-(2-(4'-(叔丁基)-[1,1'-联苯]-4-基)-3-氧代-3-((2',4',6'-三甲基-[1,1'-联苯]-4-基)氨基)丙基)苯甲酰氨基)乙烷-1-磺酸|CsnPharm

CAS No.: 1207989-09-0

Synonyms: MB-11262;RVT 1502

LGD-6972 is a novel and orally-available glucagon receptor antagonist used to treat type 2 diabetes mellitus in Phase 1 study.

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述LGD-6972 is a novel and orally-available glucagon receptor antagonist used to treat type 2 diabetes mellitus in Phase 1 study. Pharmacokinetics and pharmacodynamics study of LGD-6972 in healthy subjects and subjects with type 2 diabetes (T2DM) showed that administration of LGD-6972 could dose-dependently decrease fasting plasma glucose in all group with a maximum of 3.15 mmol/L (56.8 mg/dL) on day 14 in T2DM subjects, and also reduced plasma glucose in the postprandial state. Dose‐dependent increases in fasting plasma glucagon, but decreased glucagon levels and increased insulin levels could be observed after an oral glucose load in T2DM subjects. Inhibition of glucagon action by LGD‐6972 was associated with decreases in glucose in both healthy and T2DM subjects.
参考文献

实验方案

技术信息

CAS号	1207989-09-0	储存条件	粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6 月 -80°C:12月
分子式	C43H46N2O5S	运输	蓝冰
分子量	702.90	别名	MB-11262;RVT 1502

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

请登录您的专属账户